Pioneering biotech specializing in Antibody Drug Conjugates
Biotechnology
Type: Privately Held
About the Role
The Company is in search of a Chief Medical Officer (CMO) to spearhead the clinical and regulatory strategy for its innovative pipeline, with a focus on Antibody Drug Conjugates (ADCs) in cancer therapeutics. The successful candidate will be responsible for defining and overseeing the clinical development strategy, leading all IND, CTA, and regulatory filings, and directing Phase I-III clinical trials to ensure scientific and operational excellence. This role also involves close collaboration with R&D and translational medicine teams to optimize biomarker-driven trial design, as well as representing the company at various industry events. The CMO will play a key role in partnering with business development and commercial teams on strategic partnerships and future market planning.
Minimum Requirements
Applicants for the CMO position at the company should hold an MD or MD/PhD and have a minimum of 10 years' experience in clinical development, with a strong background in oncology drug development, including experience with Bispecifics, T-Cell Engagers, and Immune Modulators. A proven track record of advancing oncology assets from early-phase trials through regulatory approval is essential, as is strong experience in regulatory interactions with global health authorities. The ideal candidate will have the ability to thrive in a high-growth, VC-backed biotech environment and be a dynamic leader capable of driving the success of the company's pioneering therapies.
#J-18808-Ljbffr